NASDAQ$MRUS
Merus Nv · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Merus reported Q2 2025 revenue of $8.8M, a net loss of $100.9M, diluted EPS of $-2.23.
For Q2 2025, Merus reported Revenue was $8.8M, net loss was $100.9M, diluted EPS was $-2.23. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $8.8M for Q2 2025.
- Net loss $100.9M.
- Diluted EPS $-2.23.
Headline financials
Revenue & EPS history
Merus · Revenue · Quarterly
$8.83M
Forward guidance
Biopharma outlook emphasizes pipeline milestones, launch uptake, and R&D investment.
Tailwinds
- Franchise products and new indications.
- Cash runway for clinical and commercial programs.
Headwinds
- Patent cliffs and competitive entrants.
- Trial, regulatory, and reimbursement risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2025
+0.5%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+19.7%
Q3 2023
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -0.2% | +0.2% | +1.0% | |
| Q2 2025 | -2.8% | -4.2% | +0.1% | |
| Q1 2025 | -0.3% | +0.4% | +28.4% | |
| Q4 2024 | +1.5% | +3.6% | -18.8% | |
| Q3 2024 | -1.9% | +0.8% | -12.4% | |
| Q2 2024 | -1.8% | -5.8% | -4.3% | |
| Q1 2024 | -7.4% | -5.8% | +8.7% | |
| Q4 2023 | -0.9% | +2.3% | -8.1% | |
| Q3 2023 | +19.7% | — | — | |
| Q2 2023 | -11.7% | — | — | |
| Q1 2023 | +9.9% | — | — | |
| Q4 2022 | +4.0% | — | — | |
| Q3 2022 | -16.2% | — | — | |
| Q2 2022 | -8.4% | — | — | |
| Q1 2022 | +0.8% | — | — | |
| Q4 2021 | +6.4% | — | — | |
| Q3 2021 | +8.1% | — | — | |
| Q2 2021 | +3.0% | — | — | |
| Q1 2021 | -3.8% | — | — | |
| Q4 2020 | +3.2% | — | — | |
| Q3 2020 | -3.2% | — | — | |
| Q2 2020 | -1.5% | — | — | |
| Q1 2020 | +3.5% | — | — | |
| Q4 2019 | +11.9% | — | — | |
| Q3 2019 | -0.8% | — | — | |
| Q2 2019 | +7.7% | — | — | |
| Q1 2019 | +3.0% | — | — | |
| Q4 2018 | +3.8% | — | — | |
| Q3 2018 | +2.5% | — | — | |
| Q2 2018 | -2.8% | — | — | |
| Q1 2018 | -1.1% | — | — | |
| Q4 2017 | +2.6% | — | — | |
| Q3 2017 | -7.1% | — | — | |
| Q2 2017 | +5.0% | — | — | |
| Q1 2017 | +0.1% | — | — | |
| Q4 2016 | -3.5% | — | — | |
| Q3 2016 | +4.2% | — | — | |
| Q2 2016 | -1.5% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro